TrialClinical genitourinary cancer2012

Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer.

Robert J Amato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.